RV144 HIV-1 vaccination impacts post-infection antibody responses.

RV144 HIV-1 vaccination impacts post-infection antibody responses.

The RV144 vaccine efficacy clinical trial showed a reduction in HIV-1 infections by 31%. Vaccine efficacy was associated with stronger binding antibody responses to the HIV Envelope (Env) V1V2 region, with decreased efficacy as responses wane. High levels of Ab-dependent cellular cytotoxicity (ADCC)...

Full description

Bibliographic Details
Main Authors: Thembi Mdluli, Ningbo Jian, Bonnie Slike, Dominic Paquin-Proulx, Gina Donofrio, Aljawharah Alrubayyi, Syna Gift, Rebecca Grande, Mary Bryson, Anna Lee, Vincent Dussupt, Letzibeth Mendez-Riveria, Eric Sanders-Buell, Agnès-Laurence Chenine, Ursula Tran, Yifan Li, Eric Brown, Paul T Edlefsen, Robert O'Connell, Peter Gilbert, Sorachai Nitayaphan, Punnee Pitisuttihum, Supachai Rerks-Ngarm, Merlin L Robb, Robert Gramzinski, Galit Alter, Sodsai Tovanabutra, Ivelin S Georgiev, Margaret E Ackerman, Victoria R Polonis, Sandhya Vasan, Nelson L Michael, Jerome H Kim, Michael A Eller, Shelly J Krebs, Morgane Rolland
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-12-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1009101

Internet

https://doi.org/10.1371/journal.ppat.1009101

Similar Items